SELLAS LIFE SCIENCES GROUP, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other Events.

On December 13, 2022, SELLAS Life Sciences Group, Inc. issued a press release (the "Press Release") announcing positive results from its ongoing dose escalating Phase 1 first-in-human study of its highly selective CDK9 inhibitor, GFH009, in patients with relapsed and/or refractory (r/r) hematologic malignancies. As detailed further in the Press Release, results include preliminary safety and efficacy data being presented at the American Society of Hematology (ASH) Annual Meeting, along with additional data from the study achieved after the abstract cutoff date.

A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d)    Exhibits



Exhibit Number   Description
  99.1             Press Release dated December 13, 2022
104              Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses